1199SEIU Revives Bid to Drop Insurers From NY Medicaid Home Care, Citing $3.5B Savings

As New York weighs a dramatic restructuring of Medicaid home care payment, much more than just billions in state coffers hangs in the balance.

On a rain-slick morning in downtown Manhattan, a phalanx of purple-clad health-care workers chanted slogans beneath the stone gaze of City Hall. Their rally, orchestrated by 1199SEIU Healthcare Workers East, marked not just labour agitation but a broader reckoning over how New York pays for one of its most expensive public services: long-term home care.

At the heart of their demands: a revival of state control over Medicaid home care payments, jettisoning a decade-long experiment with private, third-party managed care insurers. The initiative, wrapped in the legislative garments of the Home Care Savings and Reinvestment Act, may appear as yet another Albany budget skirmish. But its implications—in terms of policy, pocketbook, and precedent—could reverberate far beyond the city’s balkanized health bureaucracy.

Currently, New York pays a panoply of private insurers to coordinate care and shepherd monthly reimbursements to home-care agencies for roughly 285,000 Medicaid enrollees. This architecture was concocted with the faith that market mechanisms and administrative oversight would rein in costs, police fraud, and perhaps, even improve patient outcomes. What transpired, at least according to critics, was rather less auspicious: spiralling administrative expenses, muddled transparency, and little to show in the way of enhanced care.

Supporters of the legislative overhaul, notably the powerful 1199SEIU and its political allies such as State Senator Gustavo Rivera, argue the evidence for a policy u-turn is now overwhelming. Their recipe is direct: excise the insurers, empower the state to run a managed “fee-for-service” system, and channel the forecasted $3.5 billion in annual savings back into Medicaid and provider wages. Even after assuming $1.8 billion in new administrative and oversight costs, proponents argue, the net savings are brisk enough to patch some of Albany’s more gaping fiscal wounds.

The industry, unsurprisingly, is unconvinced. Insurer groups, marshalled by Eric Linzer of the New York Health Plan Association, warn the legislation threatens to slash options for vulnerable patients, disrupt care for frail seniors and disabled New Yorkers, and saddle the state with new—and perhaps underestimated—administrative headaches. They stress that managed care was adopted specifically to stanch overuse and coax providers into more prudent, coordinated patterns of care.

At stake is more than institutional turf. New York Medicaid spends over $30 billion annually on long-term care; home-based services, which allow seniors and people with disabilities to avoid costly nursing homes, are both a lifeline and a budgetary albatross. Savings on this scale—if achieved—would be gargantuan by state budgetary standards, potentially buffering New York against looming federal Medicaid retrenchments.

But the plan’s impact will be felt far beyond the rooms of Albany’s technocratic mandarins. For the city’s panoply of home-care agencies, already battered by staff shortages and squeezed margins, a direct state payment model could portend either salvation or fresh uncertainty, depending on implementation. Advocates for consumers, meanwhile, worry about bureaucratic ossification and recall the protracted waits and paper-shuffling of pre-managed care Medicaid.

What of New York’s home-care workers themselves? Higher wages are the union’s North Star, with the plausible argument that squeezed administrative costs could be redirected to bolster perennially paltry pay. Such a move might just staunch the exodus of aides and stabilise a chronically churn-prone workforce. Nonetheless, the prospect of state-administered oversight chills some: one man’s streamlined efficiency is another’s red tape.

Who pays, who gains, who governs?

Considered against the backdrop of a national health-care conundrum, New York’s debate is emblematic of a larger uncertainty over managed care’s merits. Over the past decade, many states have placed their Medicaid long-term care populations into managed care plans, enticed by the promise of cost “containment” and care “coordination.” Yet, the empirical evidence for such benefits is at best equivocal. A 2022 Government Accountability Office report concluded there is scant proof that managed Medicaid outperforms traditional models in either containing costs or consistently improving outcomes.

Other states that sought refuge in managed care have not always found it cozy. Illinois, for instance, has cycled through multiple iterations of managed Medicaid, each promising—seldom delivering—efficiency and accountability. Meanwhile, patients and providers alike bemoan Byzantine billing practices and a gnawing lack of transparency. New York’s latest proposal, then, is more of a pendulum swing than a shot in the dark.

The classical-liberal perspective would welcome any serious effort to pare away administrative excess—always a bête noire of American healthcare. The rub, however, lies in execution. Direct state payment systems can be nimble or sclerotic, depending on the lethargy of the bureaucracy tasked with their stewardship. And while dumping insurance executives from the table may appear judicious, public administrators are hardly immune to waste, graft, or the deadening embrace of mediocrity.

Still, the managed care experiment in New York seems to have delivered, at best, tepid returns. When even weary-patient politicians like Senator Rivera pronounce thirteen years of managed care a “demonstrable failure,” the burden of proof arguably shifts back to its defenders. A system designed to optimise costs and care should, over time, deliver both. If instead it yields runaway administrative bills and widespread discontent, nostalgia for public management becomes less an exercise in sentiment, more a plausible alternative.

For New Yorkers, the Medicaid home-care fight is less about abstract models and more about whether the safety net can be sustained in fiscally straitened times. The path forward—whether via pared-down insurers or revitalised state oversight—merits close scrutiny, hard numbers, and a steady hand. If New York manages not only to economise but to reinvest meaningfully in patient care and worker pay, the city could yet set a precedent for large, complex states confronting similar Medicaid dilemmas.

The real test, as ever, will not be the fervour of rallies or the thud of legislative gavels, but the patient experience—timely care, continuity, and a home, not an institution, at the centre of it all. Upon that, not administrative charts or budget tables alone, should the wisdom of this shift be judged. ■